Explore: Biotech · Medtech · Drug Discovery · Diagnostics · Seed
Sofinnova Capital XI
Sofinnova Partners
Investment Thesis
Targeting early-stage medical technology and biopharmaceutical companies that seek to meet pressing unmet clinical needs through a science-driven investment approach.
About Sofinnova Capital XI
Sofinnova Partners' Capital XI is a €650M ($750M) fund focused on early-stage biopharmaceutical and medtech companies addressing urgent unmet clinical needs in areas like oncology, inflammation, immunology, CNS, and cardio-metabolic diseases. The fund primarily invests in Series A rounds, with some seed financings, across Europe and North America, leveraging the firm's multi-strategy platform and experienced team. It emphasizes leading rounds with larger-than-median cheque sizes of around €25M to support companies long-term.
Sectors
Stages
Geographic focus
Notable Investments
Actithera, Elevara, Galvanize, Haya Therapeutics, NanoPhoria
Verified 29 March 2026 · Sources: company website, Fusion42 review
Frequently asked questions
- What does Sofinnova Capital XI invest in?
- Sofinnova Capital XI invests in Biotech, Medtech, Drug Discovery, Diagnostics and Digital Health at the seed stage.
- Which geographies does Sofinnova Capital XI focus on?
- Sofinnova Capital XI focuses on United States and Europe, and is headquartered in France.
- What is Sofinnova Capital XI's typical check size?
- Sofinnova Capital XI typically writes checks of $20M to $30M.